Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial
Updated
Updated · AARP · Jun 19
Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial
3 articles · Updated · AARP · Jun 19
Summary
Phase 3 results published in The New England Journal of Medicine showed daraxonrasib doubled median survival for patients with metastatic pancreatic cancer versus chemotherapy, the current standard of care.
Patients taking the pill also reported less pain and better quality of life, adding symptom relief to the survival benefit in a disease where treatment advances have repeatedly fallen short.
Just 3% of patients with metastatic pancreatic cancer survive five years, and about 80% first reach clinics with advanced, inoperable disease because there is no routine screening test.
Pancreatic cancer is the third-leading cause of U.S. cancer death; the American Cancer Society estimates 67,530 diagnoses and about 52,740 deaths this year, with most patients older than 50.
The Phase 3 RASolute 302 trial has brought groundbreaking results for daraxonrasib, an oral therapy that is transforming treatment for metastatic pancreatic ductal adenocarcinoma. This trial showed that daraxonrasib significantly improves overall survival and progression-free survival, while also enhancing patients’ quality of life and offering a favorable safety profile. These unprecedented outcomes suggest daraxonrasib could become the new standard of care for patients who have limited treatment options, marking a major shift in how this aggressive cancer is managed and offering new hope to patients and their families.